Background
As one of the most common forms of inflammatory arthritis, gout is caused by monosodium urate (MSU) crystal deposition in and around joints [
1]. Acute symptoms of gout patients include redness, swelling, heat, pain, and even joint functional loss [
2]. Gout pain is undoubtedly one of the most serious symptoms and can be extreme, even disabling [
3]. Therefore, the development of efficient analgesia for gout pain is of very important clinic significance. Regretfully, current gout pain management is far from satisfactory [
4]. Hence, a safer and more potent drug is urgently needed for the treatment of gout pain.
Multiple lines of evidence show that macrophages play important roles in the pathogenesis of gout pain [
5]. Once activated, macrophages release numerous inflammatory cytokines, including tumor necrosis factor (TNF)α, interleukin (IL)-1β, and IL-6 [
6]. Notably, a persistent overexpression of these proinflammatory cytokines exerts algesic effects by acting on nociceptors, exacerbating pain [
7]. Furthermore, inflammation in and around the joint can recruit more inflammatory cells, causing edema and joint injury.
Among the inflammatory factors mentioned above, particular attention has been paid to IL-1β in gout pain and inflammation [
8,
9]. Previous studies have demonstrated that MSU-induced inflammatory and hypernociceptive responses are greatly decreased in mice deficient in IL-1β or the IL-1 receptor (IL-1R). In addition, the blockade of IL-1R-mediated signaling also weakens the inflammatory and hypernociceptive responses resulting from MSU crystals [
10‐
12].
Studies have shown that NOD-like receptors containing a PYD 3 (NLRP3) inflammasomes play a critical role in MSU-induced IL-1β secretion in macrophages [
5]. There are four kinds of inflammasomes, namely NLRP1, NLRP3, NLRC4, and AIM2. The NLRP3 inflammasomes play an important role in macrophages by cleaving pro-IL-1β into mature IL-1β [
13,
14]. It has been found that MSU-induced inflammation and pain responses are significantly reduced in NLRP3-deficient mice [
15].
Recently, it has been reported that cherry intake is associated with significant decreases of gout attacks [
16]. Cherry contains high levels of procyanidins, which have anti-inflammatory and anti-oxidant properties [
17,
18]. Studies also showed that the consumption of procyanidin-rich foods can lower the incidence of inflammatory diseases, including metabolic syndrome and atherosclerosis [
19]. Moreover, we have previously reported that procyanidins can strongly inhibit the morphine-induced activation of NLRP3 inflammasomes in microglia [
20]. On that basis, we hypothesized that procyanidins, a safe and effective natural product, might attenuate gout pain by inhibiting NLRP3 inflammasome activation and IL-1β maturation in macrophages.
Methods
Animals and model
Adult CD-1 mice (18–22 g) were provided by the Experimental Animal Center at Nanjing Medical University, Nanjing, China. Animals were housed five to six per cage under pathogen-free conditions with soft bedding under controlled temperature (22 ± 2 °C) and a 12-h light/dark cycle (lights on at 8:00 a.m.). The animals were allowed to acclimate to these conditions for at least 2 days before starting experiments. For each group of experiments, the animals were matched by age and body weight. All surgeries were done under anesthesia induced by chloral hydrate. 0.5 mg of MSU crystals in 10 μL of PBS was injected intra-articularly in one ankle joint. Mechanical hyperalgesia, observed as an increase in nociceptive response, was assessed by Von Fray assay [
21,
22] and expressed as mechanical paw withdrawal threshold (
g). Edema formation was described as the circumstance difference (Δmm) between the basal value and the test value.
Reagents
Procyanidins were purchased from Zelang Pharmaceutical Co. Ltd. (Nanjing, China). The purity of procyanidins was more than 95%. Procyanidins contained 1.1% monomeric, 34.2% dimeric, 24.9% trimeric, 6.7% tetrameric (totally 66.9% oligomeric procyanidins), and 33.1% polymeric procyanidins. IL-1β was from R&D Systems (Minneapolis, MN, USA). Antibodies for caspase-1 and NLRP3 were acquired from Adipogen International (San Diego, CA, USA). Antibody for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was from Sigma-Aldrich (St. Louis, MO, USA). Antibodies for phosphorylated N-methyl-D-aspartic acid receptor (NR)1 subunit (Ser896), phosphorylated extracellular regulated protein kinase (ERK; Thr202/Tyr204), phosphorylated c-Jun N-terminal kinase (JNK; Thr183/Tyr185), phosphorylated p38 mitogen-activated protein kinase (p38; Tyr182), and c-fos were from Cell Signaling Technology (Beverly, MA, USA). ROS Assay Kit was from KeyGEN (Nanjing, China). Lipopolysaccharide (LPS) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) was purchased from Gibco, and other cell culture media and supplements were purchased from HyClone (Logan, UT, USA). 3-(4, 5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) was purchased from Sunshine Biotechnology (Nanjing, China). MSU crystals were prepared by recrystallisation [
5,
11] from uric acid (Sigma-Aldrich, St. Louis, MO, USA). MSU crystals were resuspended in phosphate-buffered saline (PBS) by sonication before used. All other reagents were from Sigma-Aldrich (St. Louis, MO, USA).
Cell preparation and stimulation
Raw 264.7 was maintained in humidified 5% CO
2 at 37 °C in Dulbecco’s modified Eagle’s medium supplemented with 10% (
v/
v) FBS, penicillin (100 U/ml), and streptomycin ( U/ml). 10
5 cells were plated in 6-well plate overnight and the medium was changed to serum-free medium in the following morning, and then, the cells were treated with LPS (1 μg/ml) with or without procyanidins (1‰ DMSO) for 6 h and were stimulated with MSU crystals (200 μg/ml) for another 6 h. Cell extracts and precipitated supernatants were analyzed by immunoblotting (Additional file
1).
Western blot
Periarticular tissue of the ankle and the spinal cord segments at L1-L6 were rapidly removed and homogenized in RIPA Lysis Buffer after the animals’ deep anesthesia with chloral hydrate. The protein concentrations were determined by BCA Protein Assay (Thermo Fisher, Waltham, MA), and 30–60 μg of proteins were loaded and separated by SDS-PAGE and electrophoretically transferred onto polyvinylidene fluoride membranes (Millipore Corp., Bedford, MA). The membranes were blocked with 5% bovine serum albumin for 2 h at room temperature, probed with antibodies overnight at 4 °C with the primary antibodies, and then incubated with HRP-coupled secondary antibodies. The primary antibodies used included IL-1β (1:500), p-NR1 (1:1000), p-p38 (1:1000), p-JNK (1:1000), p-ERK (1:1000), GAPDH (1:8000), NLRP3 (1:1000), and caspase-1 (1:1000). The filters were then developed by enhanced chemiluminescence reagents (PerkinElmer, Waltham, MA) with secondary antibodies (Chemicon, Billerica, MA). Data were acquired with the Molecular Imager (Gel DocTM XR, 170-8170) and analyzed with Quantity One-4.6.5 (Bio-Rad Laboratories, Berkeley, CA, USA).
Immunofluorescence
After deep anesthesia by intra-peritoneal injection of chloral hydrate, the animal was perfused transcardially with normal saline followed by 4% paraformaldehyde in 0.1 M PB, pH 7.4. Then, L4 and/or L5 lumbar segment was dissected out and post-fixed in 4% paraformaldehyde. The embedded blocks were sectioned as 25 μm thick. Sections from each group (five mice in each group) were incubated with rabbit antibodies for c-fos (1:400). Then, the free-floating sections were washed with PBS and incubated with the secondary antibody for 2 h. After washing out three times with PBS, the samples were studied under an immunofluorescence microscope (Zeiss AX10, Germany) for morphologic details of the immunofluorescence staining. Examination was blindly carried out. Images were randomly coded and the fluorescence intensities were analyzed by Image Pro plus 6.0 software (Media Cybernetics Inc., Rockville, MD). The average green fluorescence intensity of each pixel was normalized to the background intensity in the same image.
Hematoxylin and eosin staining
Mouse joints were quickly removed from deep anesthetized mice by chloral hydrate, fixed in buffered 10% formalin for 24 h, and decalcified for 12 days in 0.5 M EDTA (pH = 8), finally embedded in paraffin [
11,
23]. Then, microtome sections (4 μm) were cut and stained with hematoxylin and eosin (H.E.).
ROS measurement
Raw 264.7 cells were plated in non-tissue-culture-treated six well dishes and stimulated with MSU (200 μg/ml) for 3 h with or without pre-treatment of procyanidins (10 μM) for 20 min. Positive controls of ROS were incubated for 30 min. After the cultivation, supernatant was removed and cells were washed with PBS. Then, the cells were incubated with 10 μM DCFHDA (to measure mitochondria-associated ROS levels) in serum-free DMEM for 0.5 h at 37 °C. After that, cells were washed with warm PBS, removed from plates with cold PBS, and subjected to fluorescence-activated cell sorting (FACS) analysis (Miltenyi MACSQuant Analyzer 10, Germany). The data were analyzed using FlowJo statistical software (Emerald Biotech Co., Ltd.).
Statistical analyses
SPSS Rel 15 (SPSS Inc., Chicago, IL) was used to conduct all the statistical analyses. Alteration of expression of the proteins detected and the behavioral responses were tested with one-way ANOVA and the differences in latency over time among groups were tested with two-way ANOVA. Bonferroni post hoc tests were conducted for all ANOVA models. Results are expressed as mean ± SEM of three independent experiments. Results described as significant are based on a criterion of p < 0.05.
Discussion
In this study, we found that the clinically used health products, procyanidins, had a significant inhibitory effect on MSU-induced NLRP3 activation. Moreover, the development of MSU-induced pain and ankle swelling was markedly attenuated by procyanidin administration.
Objectives for gout treatment include managing the symptoms of acute attacks and preventing further attacks by reducing uric acid levels in the blood. The most commonly used therapies for acute gout in general practice include the use of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids. Although these drugs have certain therapeutic effects, they present serious side effects, such as liver and kidney damage and severe gastrointestinal reactions [
3,
4,
28]. Moreover, the treatment of gout is often a long-term process. Therefore, searching for safer compounds is a very attractive strategy. Recently, cherries have attracted considerable attention and interest as a promising candidate for the prevention and management of gout [
29]. Cherries are rich in procyanidins, which are natural anti-oxidants and are currently recognized as the most effective free radical scavengers [
17,
30,
31]. Procyanidins are found in grape seeds, cranberries, black wolfberry, and other sources and are therefore widely available. The oral LD50 values of procyanidins are over 4000 mg/kg in mice, indicating a high level of safety. In our study, the high dose of 60 mg/kg was used in mice, which is equivalent to 300 mg per day in humans. Thus, the dose applied in our experiment is reasonably believed to be safe.
The intra-articular injection of MSU crystals induces the onset of pain-like behavior in mice [
10,
32]. In accordance with the findings of a previous study, the mechanical pain threshold of mice decreased obviously and allodynia was induced after an intra-articular ankle injection of MSU crystals; this effect reached a maximum 8 h after injection and lasted 72 h in our study. Moreover, procyanidin (15, 30, 60 mg/kg, PO) administration strongly inhibited MSU-induced gout pain in a dose-dependent manner, and the effect of procyanidin (30 mg/kg, PO) administration worked as well as 0.5 mg/kg of colchicine.
Evidence presented by Laurent L. Reber et al. showed that maximal ankle swelling is reached within 24 h of an intra-articular injection of MSU crystals in one mouse ankle [
11]. These results are consistent with our findings that ankle swelling reached a maximum at 24 h and the ankle circumference increased to 4.3 mm. Procyanidin (15, 30, 60 mg/kg, PO) administration decreased the circumference of the ankle to 1.7, 2.5, and 2.2 mm, respectively, after 24 h. The results of a histological assay confirmed that joint inflammation occurred in the joint space after injecting MSU crystals [
11,
33]. A model group showed a local infiltration of inflammatory cells as well as acute inflammation and tissue proliferation in the ankle joint. However, a significant reduction in these pathological changes was found in histological sections prepared from procyanidin-pretreated acute gout mice.
The MSU-induced production of IL-1β, which is mediated by the NLRP3 inflammasome activation in macrophages, is a key pathological mechanism underlying gout [
5,
34,
35]. NLRP3 inflammasome activation involves a two-step process. First, signal 1, also known as the priming signal, activates the NF-κB pathway, leading to the upregulation of pro-IL-1β and NLRP3 protein levels. Second, signal 2 is transduced by various pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Currently, several molecular mechanisms have been suggested for NLRP3 activation, including potassium efflux, lysosomal destabilization, and ROS generation [
36,
37]. Our study revealed that procyanidins significantly decreased NLRP3 expression. In addition, it has been proved that mIL1 Trap prevents and suppresses MSU-induced hyperalgesia and inflammation in a mouse model of acute gouty ankle arthritis [
10]. Consistent with these results, we found that procyanidins can markedly decrease caspase-1 and IL-1β levels, which greatly aids the alleviation of pain and ankle swelling.
We then investigated the possible mechanisms underlying NLRP3 inflammasome inhibition by procyanidins. As mentioned previously, MSU crystals induce the dissociation of TXNIP from thioredoxin in a ROS-sensitive manner, enabling it to bind to NLRP3 [
38,
39]. Evidence exists that ROS scavengers can block inflammasome activation [
40]. In accordance with this notion, we found that MSU crystals induced a very significant increase of ROS in macrophages and that procyanidins markedly inhibit MSU-induced ROS production. Our results suggest that procyanidins may inhibit NLRP3 inflammasome activation by scavenging ROS.
In addition to studying peripheral joints, we also assessed indicators of central sensitization. The
N-methyl-
D-aspartate receptor (NMDAR) activation is an essential step in both starting and maintaining activity-dependent central sensitization. NMDAR antagonists prevent nociceptive neuron hyperexcitability, which is induced by nociceptor conditioning inputs. NR1 conditional deletion even abolishes NMDA synaptic inputs and acute activity-dependent central sensitization. Moreover, NMDAR activation leads to a rapid increase of [Ca
2+], which activates protein kinase C(PKC) and calmodulin-dependent protein kinase II (CaMKII), subsequently leading to the activation of c-fos [
41,
42]. Intra-cellular pathways including PLC/PKC, phosphatidylinositol-3-kinase (PI3K), and the mitogen-activated protein kinase (MAPK) can sustain central sensitization. Among these pathways, the phosphorylation of MAPK family proteins, especially p38, has the greatest influence on pain progression. p38 phosphorylation results in the synthesis and release of numerous inflammatory mediators, including IL-1β [
43,
44]. Our study showed that MSU crystals significantly increased the levels of p-NR1, c-fos, and p-MAPK in the spinal cord, suggesting that NR1, c-fos, and MAPK may also be involved in gout pain. Procyanidins significantly inhibited the expression of p-NR1, c-fos, and p-MAPK, indicating their potential effect on the chronicity of gout pain. Since our study focused on acute pain, we will conduct further research on the mechanisms underlying chronic pain in the future.
Acknowledgements
Not applicable.